Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzyga in PANS/PANDAS
NCT04508530Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Biologic
- Countries
- 3
01
Overview
A Phase 3 trial of human normal immunoglobulin in pediatric acute-onset neuropsychiatric syndrome (PANS), sponsored by Octapharma. Started Jun 2021; status: completed.
02
Drugs
human normal immunoglobulin
03
Conditions
pediatric acute-onset neuropsychiatric syndrome (PANS)
Beyond the preview
Go deeper on NCT04508530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508530.